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Abstract
© 2016 Yakov Lomakin et al.We have previously shown that immunodominant MBP peptides
encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic
encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial,
we  investigated  changes  in  the  serum cytokine  profile  after  Xemys  administration  in  MS
patients. We observed a statistically significant decrease of MCP-1/CCL2, MIP-1β/CCL4, IL-7, and
IL-2 at the time of study completion. In contrast, the serum levels of TNF-α were remarkably
elevated.  Our  data  suggest  that  the  administration  of  Xemys leads  to  a  normalization  of
cytokine status in MS patients to values commonly reported for healthy subjects. These data are
an important contribution for the upcoming Xemys clinical trials.
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